Immune Tolerance Clinical Trial
Official title:
Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
At the completion of primary follow-up of various Medeor Transplant studies (called parent studies), subjects receiving Medeor's cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years), in order to evaluate for long-term safety.
Study MDR-105-SAE is intended to be the long-term safety monitoring extension of Medeor's cellular immunotherapy, kidney transplant clinical studies. This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Medeor's cellular products. This Master Protocol will provide up to 84 months (7 years) of additional follow-up. Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed. This study will collect the data into a centralized database allowing for continuous monitoring of any important safety signals. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
| Recruiting |
NCT06243289 -
Improving KIdney Transplantation With Cellular Therapy Study
|
||
| Recruiting |
NCT03591302 -
Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.
|
Phase 1 | |
| Completed |
NCT04525456 -
Immune Responses With Reduxium
|
N/A | |
| Recruiting |
NCT04314518 -
The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
|
||
| Enrolling by invitation |
NCT04571203 -
Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment
|
Phase 1 | |
| Recruiting |
NCT01367821 -
Immune Function in Patients With Obstructive Jaundice
|
N/A | |
| Enrolling by invitation |
NCT01117077 -
The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis
|
N/A | |
| Active, not recruiting |
NCT03744325 -
Immune Responses in Hen's Egg Oral Immunotherapy
|
N/A | |
| Completed |
NCT03383211 -
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
|
||
| Recruiting |
NCT02861872 -
Intra-peritoneal Chemotherapy in Ovarian Cancer
|
N/A | |
| Active, not recruiting |
NCT00319657 -
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
|
Phase 1/Phase 2 | |
| Completed |
NCT01538485 -
Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT
|
Phase 4 | |
| Completed |
NCT03393793 -
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
|
||
| Completed |
NCT01996774 -
Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance
|
N/A | |
| Recruiting |
NCT03292445 -
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
|
Early Phase 1 | |
| Active, not recruiting |
NCT05745792 -
Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity
|
||
| Completed |
NCT02642237 -
The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response
|
N/A | |
| Completed |
NCT01414504 -
Pneumococcal Conjugate Vaccine Followup
|
Phase 2 | |
| Not yet recruiting |
NCT06147375 -
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
|
N/A |